[68Ga] Ga-PSMA versus [18F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. a systematic review …
L Evangelista, T Maurer, H van der Poel… - European Urology …, 2022 - Elsevier
Context In the past 10 yr, several agents based on prostate-specific membrane antigen
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer
Y Wang, JR Galante, A Haroon, S Wan, A Afaq… - Nature Reviews …, 2022 - nature.com
Radiolabelled prostate-specific membrane antigen (PSMA)-based PET–CT has been shown
in numerous studies to be superior to conventional imaging in the detection of nodal or …
in numerous studies to be superior to conventional imaging in the detection of nodal or …
[HTML][HTML] Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
S Hoberück, S Löck, A Borkowetz, U Sommer… - EJNMMI research, 2021 - Springer
Background The analysis aimed to compare the radiotracers [68 Ga]-Ga-PSMA-11 and [18
F]-F-PSMA-1007 intraindividually in terms of malignant lesions, mi (molecular-imaging) TNM …
F]-F-PSMA-1007 intraindividually in terms of malignant lesions, mi (molecular-imaging) TNM …
Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer
DA Pattison, M Debowski, B Gulhane… - European Journal of …, 2022 - Springer
Abstract Introduction [18F] PSMA-1007 has potential advantages over [68 Ga] Ga-PSMA-11,
although limited prospective data evaluating diagnostic performance exist. The aims of this …
although limited prospective data evaluating diagnostic performance exist. The aims of this …
Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation
EG Arnfield, PA Thomas, MJ Roberts… - European Journal of …, 2021 - Springer
Abstract Purpose [18F] PSMA-1007 offers advantages of low urinary tracer excretion and
theoretical improved spatial resolution for imaging prostate cancer. However, non-specific …
theoretical improved spatial resolution for imaging prostate cancer. However, non-specific …
[HTML][HTML] Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
C Mingels, KP Bohn, A Rominger… - European journal of …, 2022 - Springer
Aim Despite increasing use for the detection of biochemically recurrent prostate cancer
(rPC), the diagnostic accuracy of positron emission tomography/computed tomography …
(rPC), the diagnostic accuracy of positron emission tomography/computed tomography …
Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of …
R Seifert, T Telli, M Opitz, F Barbato… - Journal of Nuclear …, 2023 - Soc Nuclear Med
18F-PSMA-1007 PET is used in the management of patients with prostate cancer. However,
recent reports indicate a high rate of unspecific bone uptake (UBU) with 18F-PSMA-1007 …
recent reports indicate a high rate of unspecific bone uptake (UBU) with 18F-PSMA-1007 …
Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients: interreader agreement and lesion detection rate of …
M Wondergem, FM van der Zant… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Over 20 different prostate-specific membrane antigen (PSMA)–targeting
radiopharmaceuticals for both imaging and therapy have been synthesized. Although …
radiopharmaceuticals for both imaging and therapy have been synthesized. Although …
Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A …
G Zhao, B Ji - American Journal of Roentgenology, 2022 - Am Roentgen Ray Soc
Please see the Editorial Comment by Sungmin Woo discussing this article. BACKGROUND.
Bone scintigraphy (BS) using 99mTc-labeled methylene diphospho-nate (99mTc-MDP) …
Bone scintigraphy (BS) using 99mTc-labeled methylene diphospho-nate (99mTc-MDP) …